Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy
- PMID: 25935484
- DOI: 10.1016/j.bbrc.2015.04.107
Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy
Abstract
Radiotherapy is a widely used treatment for many tumors. Combination therapy using anti-angiogenic agents and radiation has shown promise; however, these combined therapies are reported to have many limitations in clinical trials. Here, we show that radiation transformed tumor endothelial cells (ECs) to fibroblasts, resulting in reduced vascular endothelial growth factor (VEGF) response and increased Snail1, Twist1, Type I collagen, and transforming growth factor (TGF)-β release. Irradiation of radioresistant Lewis lung carcinoma (LLC) tumors greater than 250 mm³ increased collagen levels, particularly in large tumor vessels. Furthermore, concomitant sunitinib therapy did not show a significant difference in tumor inhibition versus radiation alone. Thus, we evaluated multimodal therapy that combined pirfenidone, an inhibitor of TGF-induced collagen production, with radiation and sunitinib treatment. This trimodal therapy significantly reduced tumor growth, as compared to radiation alone. Immunohistochemical analysis revealed that radiation-induced collagen deposition and tumor microvessel density were significantly reduced with trimodal therapy, as compared to radiation alone. These data suggest that combined therapy using pirfenidone may modulate the radiation-altered tumor microenvironment, thereby enhancing the efficacy of radiation therapy and concurrent chemotherapy.
Keywords: Lewis lung carcinoma; Pirfenidone; Radiotherapy; Sunitinib; Transforming growth factor-β.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation.Int J Oncol. 2004 May;24(5):1121-31. Int J Oncol. 2004. PMID: 15067333
-
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893. Clin Cancer Res. 2008. PMID: 18381963
-
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.Cancer Res. 2003 Jul 15;63(14):4009-16. Cancer Res. 2003. PMID: 12873999
-
Sunitinib malate for the treatment of renal cell carcinoma.Expert Opin Pharmacother. 2012 Jun;13(9):1323-36. doi: 10.1517/14656566.2012.689130. Expert Opin Pharmacother. 2012. PMID: 22607009 Review.
-
[A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].Ai Zheng. 2007 Dec;26(12):1392-6. Ai Zheng. 2007. PMID: 18076810 Review. Chinese.
Cited by
-
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy.Front Mol Biosci. 2020 Jan 31;6:160. doi: 10.3389/fmolb.2019.00160. eCollection 2019. Front Mol Biosci. 2020. PMID: 32118030 Free PMC article. Review.
-
The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.BMC Cancer. 2016 Mar 2;16:176. doi: 10.1186/s12885-016-2162-z. BMC Cancer. 2016. PMID: 26935219 Free PMC article.
-
Pirfenidone inhibits cryoablation induced local macrophage infiltration along with its associated TGFb1 expression and serum cytokine level in a mouse model.Cryobiology. 2018 Jun;82:106-111. doi: 10.1016/j.cryobiol.2018.03.012. Epub 2018 Apr 3. Cryobiology. 2018. PMID: 29621494 Free PMC article.
-
The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β.Cancer Biol Ther. 2022 Dec 31;23(1):150-162. doi: 10.1080/15384047.2022.2035629. Cancer Biol Ther. 2022. PMID: 35130111 Free PMC article.
-
Effect of captopril on radiation-induced TGF-β1 secretion in EA.Hy926 human umbilical vein endothelial cells.Oncotarget. 2017 Mar 28;8(13):20842-20850. doi: 10.18632/oncotarget.15356. Oncotarget. 2017. PMID: 28209920 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials